Please login to the form below

Not currently logged in
Email:
Password:

Covance and Sihuan Pharma partner on portfolio development

Will collaborate on preclinical and clinical stages

Covance 

LabCorp's Covance and Shandon XuanZhu, a subsidiary of Chinese R&D firm Sihuan Pharmaceutical, have announced a partnership on preclinical and clinical portfolio development.

As part of the alliance, Covance will support the global development of Sihuan Pharmaceutical's drug candidate pipeline, which consists of multiple compounds that address unmet needs across therapeutics areas including cardiovascular, metabolic, infectious disease, oncology and urology.

Honggang Bi, corporate VP and general manager of China at Covance, said: “This agreement is the first of its kind signed with a partner in the Asia Pacific region, and Covance looks forward to collaborating with Sihuan Pharmaceutical in its efforts to potentially bring global filing strategies to realisation.” 

“With multiple compounds in its development pipeline, Sihuan Pharmaceutical is a promising pharmaceutical company to watch for groundbreaking new therapies.”

Specifically, Sihuan will be provided with drug development and regulatory expertise, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as investigational new drug (IND) applications and new drug applications (NDA) in China and internationally.

Dr Frank Wu, chief scientific officer of Sihuan Pharmaceutical, commented: “The partnership is another milestone for our international collaboration and R&D team, which will enable us to accelerate the development of our pipeline, in turn helping to bring treatments to multiple markets faster, a key point of differentiation in the Chinese pharmaceutical industry.”

LabCorp announced the acquisition of full-service drug development firm Covance last November, with the deal being valued at $5.6bn.

Article by
Kirstie Pickering

2nd April 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics